Park National Corp OH lowered its position in Amgen Inc. (NASDAQ:AMGN) by 1.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 10,737 shares of the medical research company’s stock after selling 115 shares during the period. Park National Corp OH’s holdings in Amgen were worth $1,849,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Camelot Portfolios LLC bought a new stake in Amgen during the first quarter valued at about $1,429,000. Cadence Bank NA boosted its stake in Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock valued at $554,000 after buying an additional 197 shares during the last quarter. Stillwater Capital Advisors LLC bought a new stake in Amgen during the first quarter valued at about $202,000. Kornitzer Capital Management Inc. KS boosted its stake in Amgen by 70.6% in the first quarter. Kornitzer Capital Management Inc. KS now owns 38,865 shares of the medical research company’s stock valued at $6,377,000 after buying an additional 16,080 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. boosted its stake in Amgen by 21.5% in the first quarter. Adams Diversified Equity Fund Inc. now owns 127,000 shares of the medical research company’s stock valued at $20,837,000 after buying an additional 22,500 shares during the last quarter. Institutional investors own 79.12% of the company’s stock.

Amgen Inc. (AMGN) traded down 0.31% during mid-day trading on Friday, hitting $167.29. The stock had a trading volume of 1,741,936 shares. The firm’s 50-day moving average price is $174.04 and its 200 day moving average price is $168.05. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21. The company has a market cap of $122.07 billion, a PE ratio of 15.24 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.84 EPS. On average, equities research analysts anticipate that Amgen Inc. will post $12.57 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date is Tuesday, August 15th. Amgen’s dividend payout ratio is presently 41.93%.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/20/amgen-inc-amgn-stake-reduced-by-park-national-corp-oh.html.

Several equities research analysts have recently issued reports on the stock. Mizuho set a $195.00 price objective on shares of Amgen and gave the company a “buy” rating in a research report on Saturday, May 6th. UBS AG reiterated a “neutral” rating and set a $174.00 price objective (down previously from $175.00) on shares of Amgen in a research report on Monday, May 22nd. BMO Capital Markets reiterated a “buy” rating and set a $198.00 price objective (down previously from $200.00) on shares of Amgen in a research report on Monday, May 22nd. Morgan Stanley lifted their price objective on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, June 13th. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $203.00 price objective (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $186.64.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now directly owns 24,214 shares in the company, valued at approximately $3,738,641.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.